Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.17) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the business earned ($0.76) earnings per share. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Esperion Therapeutics Stock Up 1.0 %
Esperion Therapeutics stock opened at $2.08 on Monday. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.05.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on ESPR
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Articles
- Five stocks we like better than Esperion Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- Want to Profit on the Downtrend? Downtrends, Explained.
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.